ATLANTA, GA - GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company focusing on developing vaccines and immunotherapies, has announced plans to progress its Gedeptin® cancer treatment to a Phase 2 clinical trial. This follows a comprehensive review of its Phase 1b/2a trial and the earlier Phase 1 trial by GeoVax and a clinical advisory committee.
The Phase 1b/2a trial evaluated the safety and efficacy of Gedeptin in patients with advanced head and neck squamous cell carcinoma (HNSCC), who had tumors suitable for direct injection and no available curative treatments. The trial protocol involved up to five treatment cycles, each consisting of three intratumoral injections of Gedeptin over two days, followed by an infusion of the prodrug fludarabine phosphate for three days.
The review concluded that Gedeptin showed acceptable safety and efficacy levels, warranting further development. The therapy demonstrated tumor stabilization or reduction in heavily pretreated patients, without new safety concerns emerging from the trial.
The upcoming Phase 2 trial aims to establish the efficacy of Gedeptin combined with an immune checkpoint inhibitor in patients experiencing their first recurrence of squamous cell head and neck cancer. This single-cycle trial is expected to enroll around six patients, with pathologic response rate as the primary endpoint. Trial activation is anticipated in the first half of 2025.
According to J. Marc Pipas, M.D., GeoVax’s Executive Medical Director of Oncology, the combination therapy has the potential to be an active treatment against solid tumors. David Dodd, GeoVax’s Chairman and CEO, expressed optimism about the novel Phase 2 trial and mentioned ongoing development plans for Gedeptin in other solid tumor indications.
Gedeptin has been granted orphan drug status by the FDA for intratumoral treatment of accessible oral and pharyngeal cancers. The therapy uses a gene therapy strategy called Gene-Directed Enzyme Prodrug Therapy (GDEPT), where a vector delivers a gene to tumor cells, enabling them to convert a non-toxic prodrug into an active anti-tumor agent in situ.
GeoVax is also engaged in developing vaccines for infectious diseases, with a lead clinical program for a next-generation COVID-19 vaccine. The company's technologies and product candidates are supported by a robust intellectual property portfolio, and updates on clinical trials are expected later in 2024.
This report is based on a press release statement from GeoVax Labs, Inc. detailing their clinical development plans.
In other recent news, GeoVax Labs has been making substantial strides in its vaccine development and financial activities. The biotech firm has received positive outlooks from EF Hutton, Roth/MKM, and H.C. Wainwright, all initiating coverage with a Buy rating. GeoVax Labs has been recognized for its potential revenue streams from its vaccine candidates, GEO-MVA and GEO-CM04S1.
The company also secured a significant contract from the Biomedical Advanced Research and Development Authority (BARDA) for a Phase 2b clinical trial of its COVID-19 vaccine candidate, GEO-CM04S1. The direct award is approximately $24.3 million, potentially increasing to $45 million, to support clinical trial activities and manufacturing of clinical materials.
In addition to these developments, GeoVax announced a $1.3 million direct offering, selling over 800,000 shares of common stock to an institutional investor. The company has also completed patient enrollment for a Phase 1/2 study of Gedeptin in advanced head and neck cancer.
Roth/MKM's projections suggest a strong future for GeoVax Labs, reflecting confidence in the company's growth and revenue-generating capabilities. The firm also highlighted that GeoVax Labs is currently operating without any debt, which could be seen as a positive indicator of financial health.
InvestingPro Insights
As GeoVax Labs, Inc. (NASDAQ:GOVX) moves forward with its clinical trials for Gedeptin®, investors are closely monitoring the company's financial health and stock performance. According to InvestingPro data, GeoVax's market capitalization stands at a modest 10.58 million USD, reflecting the scale of the company within the biotechnology sector. The company's stock has experienced significant price volatility, with a 50.7% return over the last three months, yet also showing a substantial year-to-date price total return decrease of -61.03% as of 2024.
InvestingPro Tips suggest that GeoVax is quickly burning through cash and has been unprofitable over the last twelve months, which could be a concern for potential investors. The stock has also taken a considerable hit over the last week, with a price total return of -18.22%. These factors indicate a high-risk investment environment, which may be attributed to the inherent uncertainties of clinical trial outcomes and the capital-intensive nature of biotech research and development.
For investors interested in the detailed analysis behind these numbers, InvestingPro offers additional tips that could provide deeper insights into GeoVax's financials and stock performance. With a total of 15 InvestingPro Tips available, users can gain a more comprehensive understanding of the company's potential risks and opportunities. To access these tips, visit: https://www.investing.com/pro/GOVX.
For those considering an InvestingPro subscription, use the coupon code PRONEWS24 to receive up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. This offer may give investors the timely, in-depth data needed to make informed decisions regarding GeoVax's market prospects as it advances its Gedeptin® therapy through clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.